Marina Puchinskaya, Oncologist at “Kravira” Medical Centre, shared on LinkedIn:
“This year ESMO25 Congress is going to be rich in ctDNA research that is actively entering clinical landscape not only in lung cancer (MRD analyses from previously reported LAURA, AEGEAN and CCTG BR.31 trials), but also in colorectal cancer with several talks at Presidential Symposia. GUcancers are also actively using this new amazing instrument.
The main areas of application of liquid biopsy:
- to define postoperative treatment (PEGASUS, DYNAMIC-III and IMvigor011, also analysis of CheckMate274),
- defining anti-EGFR rechallenge in CRC (CITRIC, PARERE),
- defining systemic treatment effectiveness and prognosis (INTERCEPT, BREAKWATER),
- early cancer detection.
A separate notion of BrainStorm trial broadening the horizons of ctDNA applicability with assessing it in cerebrospinal fluid of braintumor patients.
To say nothing of a separate session on ctDNA in HNSCC (Sunday, Oct 19, Koblenz, 10.30-11.15).
However, there are still lots of practical questions on the techniques used, their standardising and accessability. A new bright world is on the doorstep. Be prepared for ctDNA will changing our practice.”
